GlassScriptPhysician profile
Manisha Makker Bansal
NPI 1639258486
$3,365.87
in general payments reported to CMS, 2019-2025
20 companies · $473 in 2025
The $473 reported for 2025 was more than what a typical Pediatric Hematology-Oncology provider received nationally (typical 2025 total: $207).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $233 · 2020: $61.53 · 2021: $1,760 · 2022: $78.91 · 2023: $123 · 2024: $637 · 2025: $473.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,152 · Education: $80.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,151.95 |
| Education | $80.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Global Blood Therapeutics, INC. | $1,783.06 | 2021-2022 | |
| Jazz Pharmaceuticals INC. | $327.16 | 2019-2025 | |
| Penumbra, INC. | $212.74 | 2025 | Indigo System, Penumbra System |
| Pfizer INC. | $188.75 | 2024 | |
| Novartis Pharmaceuticals Corporation | $174.91 | 2019-2024 | |
| Sobi, INC | $132.12 | 2019-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $123.97 | 2019-2025 | |
| Alexion Pharmaceuticals, INC. | $74.22 | 2019-2023 | Ultomiris |
| Novo Nordisk INC | $64.60 | 2019 | |
| Janssen Scientific Affairs, LLC | $63.10 | 2025 | Rybrevant |
| Servier Pharmaceuticals LLC | $43.13 | 2019-2020 | |
| Medunik USA INC. | $35.20 | 2024 | Siklos |
| Csl Behring | $31.17 | 2025 | Idelvion, Afstyla |
| Genentech USA, INC. | $24.54 | 2025 | Hemlibra |
| Uswm, LLC | $20.46 | 2024 | Iwilfin |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Rare Disease Therapeutics, INC. | $20.17 | 2025 | Xromi |
| Duchesnay USA Incorporated | $19.81 | 2019 | |
| Cashflow Solutions, LLC | $15.05 | 2025 | Pcd-52 737a (US) White, Pcd-51 731a (US) - White, Lympha Press Optimal Plus(US) Bt |
| Takeda Pharmaceuticals U.S.A., INC. | $11.71 | 2020 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Manisha Bansal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.